No Data
SymbolStock Name
Latest PriceChg%ChgVolumeTurnoverOpenPre CloseHighLowMarket CapFloat CapSharesShs Float5D %Chg10D %Chg20D %Chg60D % Chg120D %Chg250D %Chg% Year-to-dateDiv YieldTTMTurnover RatioP/E (TTM)P/E (Static)AmplitudeIndustry
US OptionsDetailed Quotes
NTLA240719P22500
- 0.05
- +0.02+66.67%
15min DelayClose Jul 18 15:55 ET
0.05High0.02Low
0.02Open0.03Pre Close11 Volume1.46K Open Interest22.50Strike Price25.00Turnover157.56%IV13.95%PremiumJul 19, 2024Expiry Date0.00Intrinsic Value100Multiplier1DDays to Expiry0.05Extrinsic Value100Contract SizeAmericanOptions Type-0.0485Delta0.0420Gamma521.80Leverage Ratio-0.0500Theta0.0000Rho-25.29Eff Leverage0.0015Vega
Intraday
- 5D
- Daily
News
We're Keeping An Eye On Intellia Therapeutics' (NASDAQ:NTLA) Cash Burn Rate
Bank of New York Mellon Posts Upbeat Earnings, Joins Archer Aviation, Rivian Automotive And Other Big Stocks Moving Higher On Friday
U.S. stocks were higher, with the Nasdaq Composite index gaining around 100 points on Friday.Shares of The Bank of New York Mellon Corporation (NYSE:BK) rose during Friday's session following better-
All You Need to Know About Intellia Therapeutics (NTLA) Rating Upgrade to Strong Buy
Stifel Maintains Intellia Therapeutics(NTLA.US) With Buy Rating, Maintains Target Price $80
Stifel analyst Dae Gon Ha maintains $Intellia Therapeutics(NTLA.US)$ with a buy rating, and maintains the target price at $80.According to TipRanks data, the analyst has a success rate of 37.7% and
Stifel Nicolaus Sticks to Its Buy Rating for Intellia Therapeutics (NTLA)
The Bull Case for Intellia Therapeutics Stock Just Got Even Stronger
Comments
How does the biotech ecosystem support advancements in personalized medicine & genomics? ![]()
• Editing Genes | $CRISPR Therapeutics(CRSP.US$ , $Intellia Therapeutics(NTLA.US$ , $Beam Therapeutics(BEAM.US$ , $Verve Therapeutics(VERV.US$ , $Editas Medicine(EDIT.US$
• Creating Therapies | $Prime Medicine(PRME.US$ , $Sana Biotechnology(SANA.US$
• Building DNA | $Twist Bioscience(TWST.US$ , $Ginkgo Bioworks(DNA.US$ , $Pacific Biosciences of California(PACB.US$ , $Illumina(ILMN.US$
• Dis...
• Editing Genes | $CRISPR Therapeutics(CRSP.US$ , $Intellia Therapeutics(NTLA.US$ , $Beam Therapeutics(BEAM.US$ , $Verve Therapeutics(VERV.US$ , $Editas Medicine(EDIT.US$
• Creating Therapies | $Prime Medicine(PRME.US$ , $Sana Biotechnology(SANA.US$
• Building DNA | $Twist Bioscience(TWST.US$ , $Ginkgo Bioworks(DNA.US$ , $Pacific Biosciences of California(PACB.US$ , $Illumina(ILMN.US$
• Dis...
7
If you had invested $10,000 in Cathie Wood's $ARK Innovation ETF(ARKK.US$ and Warren Buffett's Berkshire Hathaway $Berkshire Hathaway-B(BRK.B.US$ at different time frames here's how much you'd have today.
When $ARKK launched in 2014
Total Returns:
$BRK.B $28.6K
$ARKK $27.4K
5 years ago
Total Returns:
$BRK.B $19.7K
$ARKK $11.7K
3 years ago
Total Returns:
$BRK.B $16.4K
$ARKK $3.3K
1 year ago
Total Returns:
$BRK.B $12.8K
$ARKK $12.4K
At the start of 2024
Total Returns:
$BR...
When $ARKK launched in 2014
Total Returns:
$BRK.B $28.6K
$ARKK $27.4K
5 years ago
Total Returns:
$BRK.B $19.7K
$ARKK $11.7K
3 years ago
Total Returns:
$BRK.B $16.4K
$ARKK $3.3K
1 year ago
Total Returns:
$BRK.B $12.8K
$ARKK $12.4K
At the start of 2024
Total Returns:
$BR...
+3
$Berkshire Hathaway 13F(LIST2999.US$ $Berkshire Hathaway-A(BRK.A.US$ $Berkshire Hathaway-B(BRK.B.US$ $ARK Innovation ETF(ARKK.US$ $Coinbase(COIN.US$ $Apple(AAPL.US$ $Bank of America(BAC.US$ $American Express(AXP.US$ $S&P 500 Index(.SPX.US$ $CRISPR Therapeutics(CRSP.US$ $Intellia Therapeutics(NTLA.US$
2
2
Insiders selling shares at low prices may signal expected stock weakness. The absence of insider buying and increased selling over the past year suggest the shares aren't cheap, making the company a cautious investment.
1
Read more